neurokinin α

Neurokinin antagonist 1 is a potent is a neuropeptide antagonist that can be used to study neurological disorders.

Neurokinin A trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64680.

Neurokinin A (4-10) TFA is a tachykinin NK2 receptor agonist [1].

[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), a Neurokinin A analogue, is a selective and potent NK2 receptor (NK2R) agonist with prokinetic activity, making it valuable for researching smooth muscle contractions across various tissues through NK-2 receptor engagement [1][2][3].

(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B functions as a competitive antagonist to the Neurokinin B receptor with a pA2 value of 5.5, and does not affect Substance P or Neurokinin A [1].

(β-Ala8)-Neurokinin A (4-10), a neuropeptide, is a potent and selective agonist for the NK-2 tachykinin receptor [1].

Neurokinin Receptor (393-407), rat (SPR393–407), a fragment of the rat neurokinin 1 receptor (NK1R), undergoes rapid endocytosis and recycling to the plasma membrane upon substance P (SP) binding and is instrumental in researching neurogenic inflammation [1] [2].

[MePhe7]-Neurokinin B is a neurokinin NK-3 receptor (NK3R) agonist, exhibiting a potent agonistic activity with an IC50 value of 3 nM. It acts as a potential regulator of pulsatile gonadotropin-releasing hormone (GnRH) secretion through the activation of NK3R [1].

(Trp7,β-Ala8)-Neurokinin A (4-10) is a potent neurokinin-3 (NK3) antagonist [1].

Tyr0-Neurokinin B (Tyr-NKB), an analogue of Neurokinin B, induces contractions in the bladder [1].

Tyr0-Neurokinin A, a member of the tachykinin peptide family, acts as an agonist for the Tacr2 receptor. It is utilized in research focused on insulin resistance, obesity, and diabetes [1] [2].

[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist.

Neurokinin A(4-10) TFA(97559-35-8 free base) is a tachykinin NK2 receptor agonist[1].

[Lys5,Tyr6,mLeu9,Nle10]-Neurokinin A (4-10) (ID 305) is a selective NK2R agonist with an EC50 of 3.7 nM for hNK2R. This compound significantly reduces weight loss in diet-induced obesity (DIO) mouse models and improves Loperamide-induced urinary dysfunction in wild-type mice. It is applicable in the study of neurokinin receptor-mediated diseases such as obesity, insulin resistance, and type 2 diabetes.

MEN11467 is a novel, orally available, potent and selective peptidomimetic tachykinin NK 1 receptor antagonist for the study of acute colon cancer.

Vofopitant (GR 205171) is a potent NK1 receptor antagonist with anxiolytic and antiemetic activity for the study of post-traumatic stress disorder (PTSD).

Vofopitant dihydrochloride (GR 205171A) is an orally available, selective tachykinin NK1 receptor antagonist that inhibits [3H]SP binding to NK1 with pKi values of 9.5 and 10.6, respectively. It is a potential compound for the treatment of pathological vomiting.

Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.

Pavinetant (MLE-4901) is an orally available neurokinin-3 receptor (NK3R) antagonist used to improve menopausal symptoms.

Lanepitant 2HCl is a non-peptide neurokinin-1 receptor antagonist with analgesic and anti-inflammatory activity.Lanepitant 2HCl inhibits the binding of Substance P to the neurokinin-1 receptor, inhibits neurogenic inflammation and pain transmission, and can be used in the study of painful neuropathic disorders, such as migraines.

WIN 51,708 is a neurokinin receptor (NK1) antagonist.

Ezlopitant (CJ-11974) is a small molecule neurokinin-1-receptor (NK1) antagonist used to treat nausea, vomiting and pain.

(R)-CJ 11974: non-peptide NK1 receptor antagonist, may relieve pain and prevent chemo-induced vomiting.

Burapitant (SSR 240600) is a novel non-peptide tachykinin neurokinin 1 (NK) receptor antagonist with anti-coke oven and antidepressant activity.